Beam 制药 BEAM

John Evans has served as our Chief Executive Officer and as a member of our board of directors since January 2017. Mr. Evans has significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans previously served as a Venture Partner with ARCH Venture Partners from April 2017 to March 2021, and as a member of the board of directors of Verve Therapeutics from August 2018 to August 2022 and of Prime Medicines Inc. from September 2019 to September 2022. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, from September 2009 until April 2017, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company's pharmaceuticals practice and MedImmune. Mr. Evans holds an MBA in Healthcare Management from Wharton, a M.S. in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.

Giuseppe Ciaramella, Ph.D., has served as our President since January 2020 and previously served as our Chief Scientific Officer from February 2018 to February 2023. Dr. Ciaramella has 25 years of drug discovery experience across different therapeutic modalities, from small molecule, to biologics, to advanced medicinal products, such as mRNA. From March 2022 to September 2024, Dr. Ciaramella served as interim Chief Executive Officer and a member of the board of directors of Orbital Therapeutics, Inc. Prior to joining Beam, Dr. Ciaramella was the Chief Scientific Officer of the Infectious Diseases division of Moderna Therapeutics from 2014 until February 2018, where he was instrumental in generating some of the first LNP-encapsulated, mRNA vaccines to be dosed in humans. From 2011 until 2014, Dr. Ciaramella served as Executive Director at AstraZeneca, where he led their small molecule antiviral strategy. Between 2010 and 2011 he served as Vice President and Head of Collaborative Research at Boehringer Ingelheim, where he had responsibility for external research. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer in the U.K. where he held several leadership positions, including head of Biotherapeutics, head of Antivirals and head of the Hit Discovery Group. Dr. Ciaramella is a member of the Infectious Diseases Society of America and of the American Society of Gene Therapy. Dr. Ciaramella holds a Ph.D. in Biochemistry from University College London.

Amy Simon, M.D., has served as our Chief Medical Officer since March 2021. From April 2010 to March 2021, Dr. Simon worked at Alnylam Pharmaceuticals in roles with increasing responsibility for the clinical development of RNAi-based medicines, most recently as Vice President of Clinical Development. Previously, Dr. Simon served as a professor and a director of the Asthma Center in the Pulmonary and Critical Care Division at Tufts University School of Medicine and as a professor at Tufts Graduate School of Biomedical Science, where her laboratory conducted basic science research on asthma. She began her career in clinical practice, training as a resident in internal medicine and as a fellow in pulmonary and critical care medicine at Tufts Medical Center. Dr. Simon holds a B.A. in history and science from Harvard University, and an M.D. from Tufts University School of Medicine.

Christine Bellon, Ph.D., J.D., has served as our Chief Legal Officer since April 2019. Prior to joining Beam, she served as Senior Vice President, General Counsel and Corporate Secretary for Forma Therapeutics from October 2017 until April 2019. Prior to Forma, Dr. Bellon was Senior Vice President of Legal Affairs for Relay Therapeutics from July 2016 until October 2017. Prior to Relay, she served as Vice President of Legal Affairs and Corporate Secretary at Blueprint Medicines. Earlier in her career, Dr. Bellon practiced law and served in legal leadership roles at Hydra Biosciences and Infinity Pharmaceuticals. Dr. Bellon holds a B.S. in chemistry from Yale University; a Ph.D. in organic chemistry from the Massachusetts Institute of Technology, where she did research in the laboratory of K. Barry Sharpless; and a J.D. from Columbia Law School.

Sravan K. Emany has served as our Chief Financial Officer since December 2024. Prior to joining Beam, Mr. Emany served as Chief Financial Officer and Chief Operating Officer of Ironwood Pharmaceuticals, Inc., a biotechnology company, from December 2021 to December 2024. Prior to that, Mr. Emany served as corporate vice president, commercial excellence and chief strategy officer of Integra LifeSciences Holdings Corporation, a publicly held global healthcare company, from March 2020 to December 2021, and as vice president of strategy, treasury and investor relations before that. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles in Bank of America and BofA Securities, formerly Bank of America Merrill Lynch, for nearly a decade, culminating in his service as managing director in the mergers and acquisitions group, where he led numerous mergers and acquisitions in the healthcare sector. He also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley. Mr. Emany serves on the boards of directors of Assertio Holdings, Inc. and Kyverna Therapeutics, Inc. He holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies.

Mark C. Fishman, M.D., has served on our board of directors since May 2018. Dr. Fishman is a Professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service at Massachusetts General Hospital. In February 2019, he became a Co-Founding Partner of Aditum Bio Fund and Chairman of its Scientific and Medical Advisory Board. From 2002 through 2016, Dr. Fishman was the founding President of the Novartis Institutes for BioMedical Research (NIBR), a member of the Executive Committee of Novartis, AG, and served on the board of directors of Novartis International Pharmaceutical LTD and Chaired the board of directors of the Genomics Institute of the Novartis Research Foundation. Prior to his time at NIBR, he was the Founding Director of the Cardiovascular Research Center and Chief of Cardiology at Massachusetts General Hospital. Dr. Fishman also served as the Chairman of the board of directors of privately held Semma Therapeutics from 2016 until its sale to Vertex. He currently serves on the board of directors of the privately held companies EmbarkNeuro and Versanis Bio. He also serves as a consultant to and Scientific Advisory Board member of several other privately held biotechnology companies. Dr. Fishman graduated from Yale College and Harvard Medical School and trained in medicine and cardiology at Massachusetts General Hospital.

Graham Cooper has served as a member of our board of directors since October 2019. Since December 2025, Mr. Cooper has been the Chief Financial Officer and Chief Operating Officer of Tavo Biotherapeutics, Inc., having previously served as its Chief Financial Officer since December 2024. From March 2018 until April 2019, Mr. Cooper served as the Chief Operating Officer and Chief Financial Officer of Assembly Biosciences, Inc. Mr. Cooper previously served as the Chief Financial Officer of Receptos, Inc., from February 2013 until its acquisition by Celgene in August 2015 and Chief Financial Officer of Geron Corporation from January 2012 to December 2012. From May 2006 until March 2011, Mr. Cooper served as Chief Financial Officer of Orexigen Therapeutics, Inc. Prior to that, Mr. Cooper held roles of increasing responsibility at Deutsche Bank Securities, an investment bank, from August 1997 to February 2006, including Director, Health Care Investment Banking. He began his career as an accountant at Deloitte & Touche and was previously a C.P.A. Mr. Cooper currently serves as chairman of the board of directors of Kezar Life Sciences, Inc. Mr. Cooper received a B.A. in Economics from the University of California at Berkeley and an M.B.A. from the Stanford Graduate School of Business.

Kathleen E. Walsh has served on our board of directors since January 2021. Ms. Walsh has served as Secretary of the Massachusetts Executive Office of Health and Human Services since January 2023. Prior to her appointment as Secretary, Ms. Walsh served as President and Chief Executive Officer of Boston Medical Center since March 2010, and as Executive Vice President and Chief Operating Officer of Brigham and Women's Hospital from 2005 to 2010. Prior to that, she served as the Chief Operating Officer for Novartis Institutes for Biomedical Research and at Massachusetts General Hospital in positions including Senior Vice President of Medical Services and at the MGH Cancer Center. Prior to that, she held hospital administrator positions in a number of New York City hospitals including Montefiore, Columbia Presbyterian Medical Center, Saint Luke's-Roosevelt Hospital Center and the New York City Health and Hospitals Corporation. Ms. Walsh is a member of the Boston Public Health Commission, the Massachusetts Hospital Association, Yale University, the Association of American Medical Colleges and the Pine Street Inn. Ms. Walsh served as a director of Navigant Consulting, Inc., a management consultancy firm, from 2017 to 2020, and served on its Audit Committee; WellCare Health Plans, Inc., a health insurance company, from 2017 to 2020, and served on its Audit Committee and IT Committee. Ms. Walsh holds a B.A. and Master of Public Health from Yale University.

John Maraganore, Ph.D., has served on our board of directors since November 2021. He is the CEO and Principal of JMM Innovations, LLC and the Co-CEO of Corsera Health, a biotechnology company. He was previously the founding CEO and a director of Alnylam Pharmaceuticals (Alnylam) from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first three RNAi medicines including ONPATTRO, GIVLAARI, and OXLUMO. Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. (Millennium), most recently as senior vice president, strategic product development where he was responsible for the company's product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. Before Millennium, he served as director of molecular biology and director of market and business development at Biogen, Inc. (Biogen). At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX (bivalirudin) for injection, formerly HIRULOG and currently marketed by The Medicines Company. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is a member of the board of directors of Kymera Therapeutics, Takeda Pharmaceuticals, and Rapport Therapeutics, as well as a number of private companies. He is also a member of the board of the Biotechnology Innovation Organization (BIO), where he was Chair from 2017-2019. In addition, he serves in advisory roles for a number of investment and banking firms, including Arch Ventures, Atlas Ventures, Blackstone Life Sciences, Jefferies Financial Services, and RTW Investments.

Christi Shaw has served on our board of directors since December 2023. Since January 2026, Ms. Shaw has served as the Executive Chairperson of Kyverna Therapeutics, Inc., a biotechnology company. Previously, Ms. Shaw served as the Chief Executive Officer of Kite, a Gilead company, specializing in the development of cancer immunotherapies from August 2019 to March 2023. From April 2017 to August 2019, Ms. Shaw served as Senior Vice President of Eli Lilly Company, a global healthcare company, and President of Lilly Bio-Medicines, the business within Eli Lilly Company that comprises neuroscience and immunology. From 2014 to 2016, Ms. Shaw served as U.S. country head and President of Novartis Pharmaceutical Corporation, a global healthcare company, and from 2010 to 2014 as North American region head of Novartis Oncology. Prior to 2010, Ms. Shaw held several leadership positions at Johnson & Johnson, Inc. Ms. Shaw previously served as a director of Avantor, Inc. Ms. Shaw is also the co-founder of the More Moments More Memories Foundation to assist people with cancer and their caregivers. Ms. Shaw holds a B.B.A. in Marketing from Iowa State University and an M.B.A. from the University of Wisconsin.

Chirfi Guindo has served on our board of directors since December 2024. Mr. Guindo has also served as the Chief Marketing Officer for Merck & Co., Inc. since July 2022. He is responsible for leading the development and implementation of Merck & Co.'s long-term strategy for the Human Health portfolio spanning oncology, vaccines, pharmaceutical and pipeline products. Prior to this role, Mr. Guindo served as the Executive Vice President of Global Product Strategy and Commercialization for Biogen Inc. from November 2018 to June 2022. Mr. Guindo graduated from Ecole Central de Paris (France) with a degree in engineering and has a master's of business administration from New York University's Stern School of Business.

Ms. Bethany J. Cavanagh, Principal Accounting Officer, Treasurer and Senior Vice President, Finance.